Background
==========

Agitation and anxiety are common in critically-ill patients \[[@B1]\]. They are triggered by treatable causes, such as hypoxemia, hypoglycemia, pain, sepsis, alcohol or drug withdrawal, invasive procedures, sleep deprivation, forced body postures, uninterrupted noise and light stimulation, and the impossibility of communicating with the staff \[[@B2]\]. International guidelines suggest to face and treat first any organic and/or metabolic cause, especially pain, and to minimize environment-linked stressors. Second, they suggest the use of sedatives to ensure comfort and permit life-saving procedures \[[@B2]\]: adequate levels of sedation, therefore, represent a primary target for managing Intensive Care Unit (ICU) patients. However, sedative therapy is related to several important side effects, among which are hemodynamic instability, dysrhythmias, sepsis, ileus, delirium, and lengthening of respiratory weaning \[[@B3]\].

Recently, several papers \[[@B4],[@B5]\] have pointed out the need for lighter sedation, due both to the detrimental effects of sedative therapy itself and to the costs associated with deeper-than-needed sedation levels \[[@B6]\]. Daily interruption of intravenous short-term sedative administration is mandatory in neurosurgical or comatose patients. In a context of general ICU \[[@B7]\], Kress *et al*. demonstrated that, in association with a spontaneous breathing trial \[[@B8]\], it decreases mechanical ventilation length and reduces complications and prevalence of delirium. Analgesia-based sedation is gaining more and more popularity, due to the opiates' ability to maintain adaptation to invasive procedures while sparing, at the same time, critically-ill patients' consciousness \[[@B9]\]. However, the use of short-half-life analgesics (remifentanil) is only indicated for short-stay ICU patients, while there is no difference between opiates for patients with a length of stay (LOS) ≥ 3 days \[[@B10]\]. In 2010, Strom *et al*. demonstrated a clear indication to keep patients minimally sedated or awake by morphine boluses but without propofol \[[@B11]\].

The conscious sedation target is an innovation of the utmost relevance in the field of ICU care. Nonetheless, it has a number of detractors among intensivists, who tend to consider it unfeasible. Its unfeasibility is related to the potentially higher risk of self-removal of invasive devices \[[@B12]\] and stress/discomfort for patients \[[@B13]\]. From the ICU team prospective, it raises the possibility of an increased workload. These fears, however, are at least partially unfounded \[[@B14]\]: intensivists have to face side effects of both physical and 'pharmacological' restraint methods, continuously pursuing the best approach for patient security and healing.

Despite guideline indications and the fact that between 60% and 80% of ICUs use a specific score to evaluate the level of sedation \[[@B2]\], many physicians habitually maintain \[[@B15],[@B16]\] a deeper level of sedation than desired \[[@B17]\], probably causing avoidable side effects. The most commonly used score is Ramsay Sedation Scale (66.5%), although not validated, followed by Richmond Agitation Sedation Scale (RASS) (5.4%) \[[@B18]\], which, during the validation process, proved to be very reliable and to have low interpersonal variability both in the subgroups of the ventilated *vs.* not ventilated and the sedated *vs.* not sedated patients \[[@B19]\] (Figure [1](#F1){ref-type="fig"}). Beyond the choice of the specific drug, the most frequently used method for administering sedatives is the continuous intravenous route, because of its pharmacokinetic properties. Intravenous infusions present predictable and easy to handle onset/offset properties. Although these characteristics are necessary in short ICU stays, they can be unuseful, or even dangerous, for patients requiring \> 3 days of mechanical ventilation \[[@B17]\]: when using potent drugs, it is easy to over-administer them, albeit goals are established and adequate \[[@B15]\]. Moreover, daily awakening trials produce far-from-physiological neurological fluctuations \[[@B20]\], and continuous deep sedation does not permit patients to recall factual memories, which has been proven effective in preventing post-traumatic stress disorder (PTSD) \[[@B21]\].

![Comparison of most used ICU sedation/agitation scales highlighting the target of 'conscious sedation'.](1745-6215-14-92-1){#F1}

The enteral route for sedative administration is seldom used, even though the gastrointestinal tract is functional from the beginning of the ICU stay and in the most critical patients too \[[@B22],[@B23]\]. Our group published two studies on the feasibility of enteral administration of hydroxyzine and lorazepam for ICU patient sedation \[[@B4],[@B24]\]. Hydroxyzine, an antagonist of the H~1~ receptor, has anticholinergic, antiserotoninergic, antiemetic, and gastric antisecretory properties, and is frequently used in psychiatry and for pre-anesthetic sedation due to its neurological effects; also, since 2001, local hospital guidelines suggest the use of enteral hydroxyzine, with possible supplementation of lorazepam. Enteral melatonin is also administered as a physiological hypnoinducer (thus further saving on sedatives and analgesics): it does not cause excessive daytime sleepiness and presents interesting anti-oxidant, anti-inflammatory, and immune-modulating properties \[[@B25]\].

Enterally administered drugs are not as easy to manage as intravenous ones, due to their prolonged onset and offset. On the other hand, they provide a more stable level of consciousness, less cardiorespiratory depression, and are less expensive than intravenous drugs. They show an intrinsic impossibility to reach a deep sedation: exclusive enteral sedation has the same effectiveness (as judged by nurses) as intravenously administered drugs if a patient awake, tranquil, and well-adapted to the ICU environment is desired. Such a target can be reached in 83% of days following the first 48 h in ICU, after stabilization of clinical conditions \[[@B4],[@B24]\].

The present study arises from this scientific framework; it aims to compare enteral *versus* commonly used intravenous sedative drug administration, measuring their efficacy and feasibility in reaching and constantly maintaining an appropriate sedation level (observed RASS = target RASS ± 1) \[[@B19]\] in high-risk critically-ill patients \[[@B26]\]. The clinical target is to obtain the most 'conscious' sedation level compatible with critical illnesses, invasive procedures, and medical and nursing surveillance. This paper describes the study protocol.

Methods/Design
==============

Study design and outcomes
-------------------------

The Enteral *vs.* Intravenous Italian Trial (SedaEN) is a randomized, controlled, multicenter, single-blind trial (clinicaltrials.gov \#NCT01360346), which aims to compare the efficacy of two different clinical approaches for sedative therapies (Figure [2](#F2){ref-type="fig"}): in the control group propofol and midazolam are continuously administered through intravenous route with daily interruption \[[@B8]\]. In the intervention group, sedation is maintained through enteral hydroxyzine, with possible supplementation of enteral lorazepam \[[@B24]\]; enteral melatonin will be administered as a physiological hypnoinducer \[[@B27]\]. Participating ICU centers were selected based on their willingness to simultaneously use two very different clinical approaches; the study group is heterogeneous, resulting in a mix of both university and non-university hospitals, with ICU teams having different experience in managing enteral sedation: go to Appendix to see all the nurses and physicians in charge at each participating ICU. This choice was made to obtain the best generalizability of the results.

![**Study protocol.** During the first 2 days of treatment, clinical conditions may require 'deep sedation' (RASS target from −4 to 0), achievable only by intravenous drugs. As soon as possible, even if critical conditions persist, the 'conscious sedation' period begins (RASS target −1/0). Within 24 h after meeting enrollment criteria, patients undergo a single-blind RCT lasting until ICU discharge: in the intravenous (control) arm, patients receive only i.v. drugs, according to ABC protocol \[[@B10]\]; in the enteral (intervention) arm, patients must interrupt i.v. sedatives within 48h, maintaining enteral ones until ICU discharge \[[@B25]\]. All sedatives have to be carefully tapered off to use the lowest effective dose. NGT, Naso-gastric tube; NJT, Naso-jejunal tube; RASS, Richmond Agitation Sedation Scale; RCT, Randomized controlled trial.](1745-6215-14-92-2){#F2}

The primary objective is to achieve and maintain the sedation target: observed RASS = target RASS ±1 \[[@B19]\]. Secondary outcomes are: sedation protocol feasibility (percentage of shifts with assigned protocol violations); delirium- and coma-free days, as assessed by Confusion Assessment Method for ICU (CAM-ICU) \[[@B28]\], and RASS \[[@B29]\]; ventilation-free days; nursing assessment of sedation adequacy (communication skills, cooperation, environment tolerance) \[[@B30]\]; length of ICU and hospital stay; ICU, hospital, and 1-year mortality; sedative drug costs; adverse events and markers of sedation failure, such as self-extubation, removal of other invasive tools, unscheduled diagnostic neurological tests, anxiety, hours of sleep and agitation, use of anti-psychotics, use of physical restraints, and pharmacological antagonists (Table [1](#T1){ref-type="table"}).

###### 

Primary and secondary study outcomes

  ***Primary outcome***                                                 ***Secondary outcomes***
  --------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Percentage of efficacy (measured as observed RASS = target RASS ±1)   \- Sedation protocol effectiveness (percentage of 'protocol violation days' on the total of ICU days)
                                                                        \- Delirium- and coma-free days (respectively negative CAM-ICU and RASS ≥ −3 in all daily observations until ICU day 28)
                                                                        \- Ventilation-free days
                                                                        \- Nursing evaluation of sedation adequacy (communication skills, cooperation, environment tolerance)
                                                                        \- Overall ICU and hospital mortality
                                                                        \- Absolute mortality 1 year after ICU discharge
                                                                        \- Sedative drug costs
                                                                        \- Indirect markers of inefficacy and side effects, like prevalence of 'dangerous episodes' (self-extubation, removal of other invasive tools), length of ICU and hospital stay, use of anti-psychotic drugs as indirect marker of delirium, indicators of sedation failure (use of physical restraints, antagonists administration like flumazenil or naloxone), sepsis prevalence.

Study population
----------------

All high-risk critically-ill patients (SAPS II ≥ 32, estimated length of mechanical ventilation ≥ 3 days) \[[@B26]\] (Figure [3](#F3){ref-type="fig"}) are eligible, within the first 24 h after they meet inclusion criteria. Figure [3](#F3){ref-type="fig"} describes an ICU population of 7,877 critically-ill patients enrolled in an international, multicenter, observational trial: elderly in European intensive care units (ELDICUS). They had a mortality rate of 22.6% at 28 days and 29.6% at 90 days. This figure highlights the subgroup of patients with both severity and intensity of treatment higher than median values, whose clinical outcome is most likely to be highly influenced by therapeutic choices. Table [2](#T2){ref-type="table"} summarizes inclusion and exclusion criteria, including patients who are expected to need a kind or amount of sedatives different from usual care, because of their past or current medical history.

![**Selection criteria for high-risk critically-ill patients.** Patients most representative of critical population present both high severity (SAPS higher than median) and high intensity (ventilation days higher than median) criteria. In these ICU patients, each therapeutic choice possibly influences clinical outcome \[[@B26]\].](1745-6215-14-92-3){#F3}

###### 

Inclusion and exclusion criteria - patients are included if thay meet all three criteria, and are excluded if they meet one or more of the following criteria

  ***Inclusion criteria***                                               ***Exclusion criteria***
  ---------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------
  SAPS II ≥ 32 points                                                    Neurosurgical patients
  Estimated length of mechanical ventilation at ICU admission ≥ 3 days   CNS diseases (epilepsy, stroke, dementia, post-anoxic coma)
  Age ≥ 18 years                                                         Liver encephalopathy (Child-Pugh C)
                                                                         Previous psychiatric or cognitive pathology
                                                                         Allergy to medications used in the study
                                                                         Absolute contraindications to the use of enteral route (nasogastric tube, nasojejunal tube, jejunostomy, ileostomy are all considered acceptable)
                                                                         Pregnant or breast-feeding patients
                                                                         Death is deemed imminent and inevitable or the patient has an underlying disease process with a life expectancy of \< 90 days

Study procedures
----------------

Both protocols are tailored to deliver the lowest effective doses of sedatives in order to reach as soon as possible and constantly maintain the target sedation level (RASS = 0) \[[@B14]\]. Moreover, ICU teams should try, whenever possible, to reduce or suspend all the sedative drugs. Physicians reconsider their target at every shift: if they choose a deep sedation goal (RASS \< −3), their decision must be adequately justified. Even though every center is strongly advised not to make protocol violations, they are always feasible, provided they are explained and recorded. Intravenous boluses of fentanyl/morphine + propofol/midazolam are allowed in the enteral arm to perform and complete extemporary invasive/painful/surgical procedures; this will never represent a protocol violation.

In the control arm of the study ('intravenous'), propofol or midazolam (maximum: propofol 6 mg/kg\*h; midazolam 0.2 mg/kg\*h) are continuously administered intravenously from ICU admission until discharge, with daily interruption \[[@B8]\]. Enteral sedatives are always considered a protocol violation (Figure [4](#F4){ref-type="fig"}).

![**Control arm: intravenous sedation, based on literature evidence\[**\[[@B2]\]**,**\[[@B8]\]**\].**](1745-6215-14-92-4){#F4}

In the intervention arm ('enteral'), intravenous sedatives are allowed during the first 48 h after ICU admission, in association with enteral sedatives. This is done to allow a more manageable sedative strategy during the first hours of ICU stay, when the highest number of procedures is performed and patients show the highest clinical instability. However, any continuous infusion must be stopped within 48 h. Sedation will be maintained through enteral hydroxyzine (maximum 600 mg/die) with the possible supplementation of lorazepam (maximum 16 mg/die). Enteral melatonin is administered from ICU admission until discharge, 3 mg b.i.d. (20:00 and midnight). Any intravenous sedative represents a protocol violation if target RASS ≥ −3. In case of clinical indication for deeper sedation, once enteral drugs are maximized, the necessary intravenous administration is not considered a protocol violation (Figure [5](#F5){ref-type="fig"}).

![**Intervention arm: enteral sedation.** Local guidelines for conscious enteral sedation, adopted since 2001 in A.O. San Paolo - Polo Universitario, Milan, Italy following a multidisciplinary commission composed by intensivists, neurologists, and psychiatrists.](1745-6215-14-92-5){#F5}

Analgesia, delirium, and respiratory weaning will be managed in accordance with local guidelines; to help manage particularly complex cases, three flowcharts are proposed, for pain, sedation, and delirium (Figures [6](#F6){ref-type="fig"}, [7](#F7){ref-type="fig"} and [8](#F8){ref-type="fig"}). They stress the importance of considering all those factors (that is, organic and metabolic causes, presence of invasive tools, pain, and so on) that could contribute to agitation and anxiety, and should be corrected before administering any neuroactive drug. Participating centers must use analgesics (particularly opiates) only in case of pain (Verbal Numeric Rating (VNR) \> 3; or Behavioral Pain Scale (BPS) \> 6), \[[@B31]\] avoiding analgesia-based sedation. If delirium appears (CAM-ICU +), after correcting underlying causes, the non-pharmacological protocol will be applied and potential deliriogenic therapies stopped; only after these interventions may physicians prescribe haloperidol (1 mg per os, maximum 10 mg/die), or any other antipsychotic drug, according to local guidelines.

![Bedside flowchart for pain management in ICU patients.](1745-6215-14-92-6){#F6}

![Bedside flowchart for sedation/agitation management in ICU patients.](1745-6215-14-92-7){#F7}

![Bedside flowchart for delirium management in ICU patients.](1745-6215-14-92-8){#F8}

Both groups will start enteral nutrition during the first 24 to 48 ICU hours, while parenteral nutrition will be administered only to achieve the caloric target if not reached by enteral route \[[@B32]\]. In case of gastric residual volume \> 200 mL/4h, prokinetic drugs will be used according to local guidelines; if the problem persists for \> 2 days, a post-pyloric access is recommended: auto-propulsive naso-jejunal tube (NJT), or guide-wired NJT positioned under fluoroscopy (Figure [9](#F9){ref-type="fig"}), endoscopic-positioned NJT, post-pyloric tube manually positioned by the surgeon, or percutaneous jejunostomy during open-abdomen operations.

![Post-pyloric access: guide-wired nasojejunal tube positioned under fluoroscopy.](1745-6215-14-92-9){#F9}

All patients are maintained in sitting semi-orthopnoeic position (headboard of the bed elevated between 30° and 45°). Physiotherapy is started as soon as possible, according to local guidelines.

Randomization process
---------------------

Patient allocation to the two treatment groups is made by an online process over a password-protected, interactive, centralized website, through specific software, available 24/7, expressly designed for this study (<http://www.sedaen.it> (Figure [10](#F10){ref-type="fig"})). After checking for inclusion and exclusion criteria, trained staff at each participating center obtain informed consent according to local Ethical Committee indications. Patient allocation occurs using a minimization algorithm \[[@B33]\], to maintain groups balanced within each center, according to those characteristics potentially influencing the study outcomes, as indicated by the SedaEN Steering Committee. Each variable's weight is: Simplified Acute Physiology Score (SAPS II) \[[@B34]\], 10; type of admission, 6; chronic or acute kidney failure, 5; severe sepsis or septic shock, 4; COPD, 3; age, 2; sex, 1. Using this method, the first patient enrolled in each center is randomly assigned to one of the study arms by a computer-generated order. This allocation is the basis for all subsequent assignments for that center, unless there is perfect balance among admission characteristics; in this case, the next patient is once again randomly allocated. A full explanation of the minimization process is available at <http://www.elekton.it/randomind>. Once a patient is assigned, due to the intention-to-treat design of the study, the change of protocol arm is not possible for any reason.

![**Home pages of the two Internet websites specifically designed for the SedaEN study.**<http://www.sedaen.it> is the website where patients are randomized and patients' data are recorded, while <http://www.sedaicu.it/en> is available to all nurses and physicians 24/7, containing materials for the correct use of validated tools for neurological monitoring of critically-ill patients, both in Italian and English.](1745-6215-14-92-10){#F10}

Data collection and management
------------------------------

Trained staff (see Appendix) record data and fill in the web-based collection forms. Before group assignment, baseline patient demographics and characteristics for minimization are collected. From the day after patient allocation, information on daily physiological parameters are used to derive SOFA score \[[@B35]\] and level of care \[[@B36]\]. Three times a day, once per shift, in addition to vital and lab parameters, neurological monitoring through validated tools is performed and recorded. In particular, target RASS (established by the physician in charge) and the actual RASS, \[[@B19]\] that is the 'prevalent level' in the shift, VNR for anxiety and pain (BPS if patient is uncooperative) \[[@B31]\], CAM-ICU \[[@B28]\], and nursing evaluation on adequacy of prescribed sedative therapy is recorded. Protocol violations and their clinical motivation, along with doses of analgesics, sedatives, and antipsychotics used for 'rescue therapy', are also recorded.

At ICU discharge, patient data and vital status, length of mechanical ventilation, and ICU stay are recorded. At hospital discharge, length of stay and mortality are registered. One year after ICU discharge, mortality will be assessed through a phone interview.

The web-based data management system allows for *ad hoc* and automatic validation and consistency checks as well as immediate query resolution. This ensures data accuracy and completeness; it allows timely access to 'clean' data for analysis purposes. Finally, a screening log will be maintained at each participating center to record ICU admitted patients who were considered ineligible.

Ethical issues
--------------

All participating centers obtained local ethics committee approvals to conduct the trial: 'Comitato Etico' of A.O. San Paolo - Polo Universitario, Milano; 'Comitato Etico Interaziendale' for the centers A.O.N. SS. Antonio e Biagio e Cesare Arrigo, Alessandria, and A.O. Ospedale Cardinal Massaia, Asti; 'Comitato Etico' of A. O. Ospedale Civile di Desio (MI); 'Comitato Etico' of A.O. Ospedale Civile di Legnano (MI); 'Comitato etico' of Nuovo Ospedale Civile Sant'Agostino Estense, Modena; 'Comitato Etico' of A.O. San Gerardo, Monza (MB); 'Comitato Etico' of A.O.U. San Luigi Gonzaga, Orbassano (TO); 'Comitato Etico' of I.R.C.C.S Ospedale Maggiore Policlinico, Milano; 'Comitato Etico' of I.R.C.C.S. San Matteo, Pavia; and 'Comitato Etico' of A.O. San Giovanni Bosco, Torino. Written informed consent is mandatory for all able patients. In cases of impossibility to obtain it, a written declaration of received information is collected from relatives, according to local ethics committee indications. As soon as neurological conditions improve, patients are duly informed of the study, and their written consent is obtained. Patients or their next of kin have the opportunity to withdraw from the study at any time.

Sample size and power
---------------------

A study sample size of 300 patients was calculated in order to observe a 15% difference in the prevalence of sedation adequacy (observed RASS = target RASS ±1) between the two study arms: such a difference is considered clinically relevant and likely to influence practice. Considering that the enteral approach allowed for 83% adequacy in an observational monocentric study \[[@B24]\], it was considered necessary to enroll 141 patient per arm (power 80%, alpha 0.05). Considering missing data, 300 patients were expected to be enrolled among the 12 centers. Each center had to enroll at least 20 patients during the study period, otherwise it would not be considered for the planned sub-analysis comparing the participating ICUs.

Statistical analysis
--------------------

Statistical analysis will be conducted on an intention-to-treat basis, due to the potential high violation rate from the assigned protocol. A 'per-protocol' planned analysis will be conducted, excluding patients receiving no analgesic or sedative drugs, having an ICU stay \< 48 h, or presenting assigned protocol violations in every ICU day. Subgroup analyses are planned *a priori* to obtain a comparison: (1) among participating ICUs, because of dissimilar ability to manage the two different sedative protocols; (2) between septic and non-septic patients (greater delirium prevalence, lower levels of endogenous melatonin) \[[@B37]\]; and (3) between different age groups (greater delirium prevalence if age \> 70 years, higher risk of paradoxical effect of benzodiazepines, impairment of renal and hepatic function) \[[@B38]\].

An '*ad interim*' analysis was planned after the enrollment of 70 patients per group. Its purpose was to identify any potential safety issues or test for early efficacy. It was evaluated by the SedaEN Steering Committee (see Appendix): since no safety issues were reported, and interesting trends were found about the main outcome, patients' enrollment was completed according to the established planning.

Baseline patient characteristics and single-observation outcomes will be analyzed by Student *T*-test for continuous measures if normally distributed; by Wilcoxon rank-sum test if not normally distributed; by Fisher's exact test for categorical measures. Appropriate (linear, logistic, or Poisson) regression models will be generated for the identification of the determinants of outcomes and for the correction for baseline covariates.

Mortality will be compared using relative risks and 95% confidence intervals. Survival times will be compared by means of the log-rank test and presented as Kaplan-Meier curves without adjustment for baseline covariates and as multivariate Cox proportional hazard analysis.

Analysis for repeated measures will be performed for data recorded during the whole ICU stay, that is, the main outcome: comparisons will be made by cross-sectional time-series regression models (random-effects, and population-averaged linear models) or by multilevel mixed-effects Poisson regressions, when appropriate \[[@B39]\]. Sepsis prevalence during the whole ICU stay will be analyzed by conditional fixed-effects logistic regression. This statistical approach was chosen to simultaneously analyze the net effect of group assignment; the effect of time spent in ICU; the cumulative sedative effect, calculated by multiplying the group (enteral = 1, intravenous = 0) and the ICU day from group assignment, to highlight the adjunctive effects of the daily repeated sedative administration.

For the *a priori* planned sub-analyses, outcomes and methods will be the same as for the main analysis. Missing data regarding the main outcome should be absent or very few, since the centralized website needed the completeness of data in order to permit the final validation of each patient's form. For the other data, missing observations will be handled with multiple imputations as calculated by the statistical package Stata 12 (Stata Corporation, College Station, TX, USA). This software will be used for all the statistical analyses.

Discussion
==========

This 'educational research' project aims both to compare two sedative strategies and to highlight the need for a profound cultural change, improving outcomes by keeping critically-ill patients awake.

Study limitations
-----------------

This study has some limitations: first, it is a single-blind study, since the two different routes to give sedatives do not permit staff blindness to drug administration. To cope with this problem, great efforts in order to maintain the same sedation target in both study arms were made: many ready-to-use tools were provided to nurses and physicians; an oral presentation was made by the principal investigator in all participating centers; two investigators' meetings (on March 23 and September 15, 2012) were organized. Second, two relevant essentials of the study (conscious target and use of validated tools for neurological monitoring) were introduced in some of the participating centers together with the beginning of the study; in others, they were already consolidated in clinical practice. Since one of the goals is the promotion of a new culture of sedation management, the simultaneous presence of different skills among intensivist staff makes the results more generalizable, even if they come from non-homogeneous ICUs.

Training for ICU staff: the new concept of educational research
---------------------------------------------------------------

Although conscious sedation is now recognized as valid by solid scientific evidence, international literature widely describes cultural and organizational difficulties in introducing it into clinical practice, and in using daily validated tools for neurological monitoring of ICU patients \[[@B14]\].

Our study aims to be part of an 'educational research' project: the comparison of two different protocols, within the framework of a common target (conscious sedation) represents some kind of innovation, thus fulfilling a scientific goal, since at the present time both these protocols are described in the Italian guidelines \[[@B40]\]. Beyond scientific questions, the introduction of validated monitoring instruments into clinical practice, required for data collection, moves closer to international indications. Through teaching and using validated tools, ICU operators become aware of the need for a cultural change, in order to improve critically-ill patient care by keeping them awake. In this context, an important part of the present trial is to offer training materials, available 24/7 for everyday use, through a dedicated free-access website (<http://www.sedaicu.it/en>), both in Italian and English, which offers continuous education to physicians and nurses through CME courses.

Trial status
============

Patients' enrollment lasted from January 24 to December 31, 2012. A total of 348 patients have been randomized, through a centralized website, using the specific software expressly designed for this study. Figure [11](#F11){ref-type="fig"} shows the enrollment course across the participating centers.

![**Number of patients admitted to the SedaEN participating ICUs from January 24 to December 31, 2012.** In blue: all patients recorded on the website. In light blue: patients randomized. In light green: patients from centers included in the planned sub-analysis comparing the participating ICUs (at least 20 per center). In green: patients from centers meeting the requested number of enrolments (30 patients). ALE, A.O.N. SS. Antonio e Biagio e Cesare Arrigo, Alessandria; AST, A.O. Ospedale Cardinal Massaia, Asti; DES, A. O. Ospedale Civile di Desio (MI); HSP, A.O. San Paolo - Polo Universitario, Milano; LEG, A.O. Ospedale Civile di Legnano (MI); MOD, Nuovo Ospedale Civile Sant'Agostino Estense, Modena; MON, A.O. San Gerardo, Monza (MB); ORB, A.O.U. San Luigi Gonzaga, Orbassano (TO); POL, I.R.C.C.S. Ospedale Maggiore Policlinico, Milano; PVU e PVD, I.R.C.C.S. San Matteo, Università degli Studi di Pavia; TOR, A.O. San Giovanni Bosco, Torino.](1745-6215-14-92-11){#F11}
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Gaetano Iapichino (Study Chair, Dipartimento di Fisiopatologia medico-chirurgica e dei trapianti, Università degli Studi di Milano, A.O. San Paolo, Milano), Alberto Morabito (Chair of Statistics, Dipartimento di Scienze cliniche e di comunità, Università degli Studi di Milano, A.O. San Paolo, Milano), Martin Langer (Dipartimento di Fisiopatologia medico-chirurgica e dei trapianti, Università degli Studi di Milano, Fondazione I.R.C.C.S. - Istituto Nazionale dei Tumori, Milano), Roberto Malacrida (Cure Intense, Ospedale Regionale di Lugano, Switzerland), Franco Valenza (Dipartimento di Fisiopatologia medico-chirurgica e dei trapianti, Università degli Studi di Milano, I.R.C.C.S. Ospedale Maggiore Policlinico, Milano), Marco Rambaldi (Nuovo Ospedale Civile Sant'Agostino Estense, Modena), Giovanni Mistraletti (Dipartimento di Fisiopatologia medico-chirurgica e dei trapianti, Università degli Studi di Milano, A.O. San Paolo, Milano).
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